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Accumulation of unfolded proteins within the endoplasmic retic-
ulum (ER) of eukaryotic cells triggers the unfolded protein re-
sponse (UPR), which activates transcription of several genes en-
coding ER chaperones and folding enzymes. This study reports that
conversion of dolichol-linked Man2–5GlcNAc2 intermediates into
mature Glc3Man9GlcNAc2 oligosaccharides in primary human adult
dermal fibroblasts is also stimulated by the UPR. This stimulation
was not evident in several immortal cell lines and did not require
a cytoplasmic stress response. Inhibition of dolichol-linked
Glc3Man9GlcNAc2 synthesis by glucose deprivation could be coun-
teracted by the UPR, improving the transfer of Glc3Man9GlcNAc2 to
asparagine residues on nascent polypeptides. Glycosidic process-
ing of asparagine-linked Glc3Man9GlcNAc2 in the ER leads to the
production of monoglucosylated oligosaccharides that promote
interaction with the lectin chaperones calreticulin and calnexin.
Thus, control of the dolichol-linked Glc3Man9GlcNAc2 supply gives
the UPR the potential to maintain efficient protein folding in the ER
without new synthesis of chaperones or folding enzymes.
Cells possess complex mechanisms to deal with stress causedby changes in the extracellular environment or in the cell’s
own physiology. In eukaryotes, the unfolded protein response
(UPR) of the endoplasmic reticulum (ER) has become a model
for specific signaling and transcriptional events that respond to
stress (1). The UPR is distinct from cytoplasmic stress responses
and can be triggered by treatments that cause unfolding of
proteins in the lumen of the ER. By a remarkable ER-to-nucleus
signaling pathway involving the transmembrane kinase Ire1p, the
UPR results in de novo synthesis of ER proteins (such as the
‘‘glucose-regulated proteins’’ GRP78 and GRP94) that aid pro-
tein folding (1). It has been suggested that the UPR may be
activated in response to rapid increases in the production of
secreted and cell-surface proteins (1) because such increases
might exceed the folding capacity of the ER.
Since the late 1970s, there has been a clear link between sugar
metabolism and the UPR. The UPR can be induced by extended
glucose starvation for periods of 24 hr or more (2–5) or by
inhibitors of asparagine-linked protein glycosylation, such as
tunicamycin (TN) (1), or glycoprotein processing, such as cas-
tanospermine (CSN) (6, 7). It is likely that UPR induction by
these conditions is caused in part by interference with the ER
chaperones calnexin and calreticulin. Both are lectins involved in
protein folding and oligomerization, requiring specific mono-
glucosylated asparagine-linked oligosaccharides on target pro-
teins to initiate binding (8–12). TN (13) inhibits synthesis of the
dolichol-linked, i.e., lipid-linked oligosaccharide (LLO)
glucose3mannose9N-acetylglucosamine2 (Glc3Man9GlcNAc2)
(14, 15), and therefore prevents asparagine-linked glycosylation
catalyzed by oligosaccharyltransferase. CSN inhibits deglucosy-
lation of oligosaccharides after transfer to protein (16), prevent-
ing direct trimming to the monoglucosylated form (9, 10) as well
as later reglucosylation (17), and thereby blocking interaction
with calnexin and calreticulin. Glucose starvation can cause
accumulation of truncated LLO intermediates, such as
Man5GlcNAc2 (18–21) that are transferred to protein less
efficiently than Glc3Man9GlcNAc2 (22, 23) and are not readily
converted into monoglucosylated structures (17).
Thus, proper sugar metabolism and LLO formation are
essential for normal protein folding in the ER. Because the UPR
had been shown to control the concentrations of a number of ER
chaperones and folding enzymes, experiments were designed to
determine whether the UPR might also regulate LLO synthesis.
Materials and Methods
Cell Cultures. The following primary cultures of normal human
adult dermal fibroblasts were tested: CRL 1987 (used for all
experiments presented), CRL 1904, and CRL 1892 [American
Type Culture Collection (ATCC)]; F1-7, F1-8, and F24-4
(National Psoriasis Tissue Bank, Dallas); and PN1.1 (Univer-
sity of Texas Southwestern Skin Disease Research Core,
Dallas). Chinese hamster ovary (CHO)-K1 cells were as
described (24), A375 melanoma cells were from the ATCC,
HeLa cells were from David Russell (University of Texas
Southwestern Medical Center, Dallas, TX), and RAW 264.7
cells were from Richard Kitchens (University of Texas South-
western Medical Center).
UPR-Inducing Treatments. CSN (either purchased from Matreya,
Pleasant Gap, PA or obtained as a gift from Alan Elbein,
University of Arkansas for Medical Sciences, Little Rock, AR)
blocks processing glucosidases I and II and hence the calnexiny
calreticulin cycle (16). DTT (Sigma) was used to reduce disulfide
bonds (25). Azetidine-2-carboxylic acid (Sigma) was used to
replace proline in nascent polypeptides and prevent isomeriza-
tion (26). Geldanamycin (Calbiochem), which blocks heat shock
protein (HSP)90-type chaperones, was used to inhibit GRP94
function (27). Treatments at 42°C (for 2 hr, unless stated
otherwise) were used to thermally denature proteins.
Preparation of LLO. A total of 100,000 human adult dermal
fibroblast (HADF) cells were seeded in untreated 100-mm Pyrex
dishes and grown at 37°C in a humidified 5% carbon dioxide
atmosphere for 2–4 days in 10 ml of RPMI 1640 medium
supplemented with 10% FBS. Cells were refed growth medium
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within 24 hr prior to metabolic labeling. Longer refeedings gave
variable results, possibly the result of associated stresses such as
nutrient deprivation (data not shown). In some experiments, the
UPR was deliberately induced prior to metabolic labeling. For
labeling, the growth medium was replaced with 1 ml of RPMI
1640 medium containing 0.5 mM D-glucose and 2.3 mM D-[2-
3H]mannose (15–20 Ciymmol; Amersham Pharmacia). Care was
taken not to exceed this amount as the mass of the [3H]mannose
itself contributes significantly to the LLO mass. Because serum
contains both glucose and mannose, dialyzed FBS (10%) was
used during labeling. After labeling for 20 min at 37°C, dishes
were placed on ice, and the medium was removed. After rinsing
with ice-cold PBS, cells were scraped directly into 10 ml of
chloroformymethanolywater (10:10:3). This was followed by
centrifugation (2,000 3 g for 15 min; the pellet was used for
glycopeptides as described below), evaporation of the superna-
tant to dryness, cleavage of the pyrophosphate bonds of the LLO
with 0.1 M HCl, partitioning between butanol and water,
reduction with sodium borohydride, desalting with a mixed-bed
ion exchange resin, analysis of 3H-labeled oligosaccharides by
silica HPLC, and comparison to known standards (28).
Preparation of Glycopeptides and Analysis by Endoglycosidase H
(endo H) Digestion. After extraction of cell samples, glycopeptides
(obtained by trypsin digestion of the insoluble residues) were
treated in the absence or presence of 5,000 units of endo H (New
England Biolabs) and fractionated with a 1 3 45 cm column of
Bio-Gel P-4 (superfine) in PBS at 0.1 mlymin to separate
3H-labeled glycopeptides and released 3H-labeled oligosaccha-
rides (29). Only LLO-type oligosaccharides with six or more
mannose residues can be cleaved by endo H.
2-Deoxyglucose Uptake. Triplicate cell cultures were labeled for 10
min at 37°C with glucose-free RPMI 1640 containing 10%
dialyzed FCS, 2 mCiyml 2-deoxy-D-[3H]glucose (10 Ciymmol;
Sigma), and 2 mM 2-deoxy-D-glucose. Cells were washed three
times with ice-cold PBS and solubilized with 2 ml of 1% SDS, and
the associated radioactivity was determined by liquid scintilla-
tion spectrometry.
Results
Studies were initiated to determine whether the UPR might have
a positive regulatory effect on LLO synthesis in addition to its
role in the maintenance of chaperones and folding enzymes.
Mammalian cells are typically cultured in medium containing
5–10 mM D-glucose, but to enhance labeling of LLO with
D-[2-3H]-mannose, it is common to reduce the glucose concen-
tration to 0.5–1.0 mM. As shown previously by many laborato-
ries, with essentially all immortal cell lines, LLO synthesis is
unaffected by such changes, and mature Glc3Man9GlcNAc2 is
the prominent LLO (CHO-K1, Fig. 1A; RAW 264.7, HeLa, and
A375 melanoma cells, data not shown). Unexpectedly, primary
HADF grown with 5 mM glucose and then labeled briefly for 20
min in 0.5 mM glucose with 2.3 mM [3H]mannose displayed
extensive differences in their LLO profiles (Fig. 1B). The
intermediates Man2–5GlcNAc2 became the major species, al-
though there was little change in the relative glucosylation of the
remaining Man9GlcNAc2. Glc3Man9GlcNAc2 represented an
average of 56.5 6 3.1% (n 5 5) of all 9-mannose oligosaccharides
labeled in 5 mM glucose and 53.1 6 2.9% (n 5 5) when labeled
in 0.5 mM glucose. These effects were dependent on glucose
concentration (Fig. 1D), and if 5 mM glucose was maintained
during labeling, the HADF pattern resembled that of CHO-K1
cells labeled with 0.5 mM glucose (Fig. 1C). The same results
were obtained whether cells were labeled in 0.5 mM glucose for
20 or 60 min, and there was no 3H-labeled LLO detectable after
a 5-min chase with unlabeled mannose. This demonstrates that
the results of the 20-min labeling period represent a steady state.
Further, the LLO pool in HADF cells is short-lived, and a brief
f luctuation of the extracellular glucose concentration can dra-
matically alter LLO synthesis. Thus, HADF were chosen for
further study because the LLO pathway was potentially more
susceptible to regulation than the pathway in immortalized lines.
HADF were then incubated briefly (20 min) with [3H]man-
nose and 0.5 mM glucose to accumulate truncated LLO and
tested for effects of the UPR (Fig. 2A, Left). Any of five
treatments able to induce the UPR applied either during (di-
sulfide disruption by DTT) or prior to labeling (processing
glucosidase inhibition by CSN; inhibition of proline isomeriza-
tion by azetidine-2-carboxylic acid; inhibition of GRP94 with
geldanamycin; and 42°C heat shock with either 0 or 6 hr of
recovery) consistently counteracted truncation of LLO, increas-
ing Glc3Man9GlcNAc2 by 3- to 15-fold depending on the specific
stress. While each treatment also had effects on other cellular
processes, inhibition of protein folding in the ER was the only
effect in common. In addition, glucosidase inhibition and disul-
fide disruption would be expected to affect protein folding in the
ER, not the cytoplasm. Swainsonine, an inhibitor of Golgi
mannosidase II that was not expected to affect ER function, had
no effect on GRP78 mRNA or LLO synthesis (data not shown).
The effects of TN and thapsigargin, two other well known
inducers of the ER UPR, were not evaluated because the former
eliminates LLO synthesis (13) and the latter, for unknown
reasons, inhibited labeling of the LLO pool (data not shown).
Fig. 1. LLO synthesis in CHO-K1 and HADF cells. (A–C) LLO were metabolically
labeled with [3H]mannose, and released oligosaccharides were analyzed by
HPLC. Arbitrary units from an in-line tritium detector are given on the y-axis.
The position of Glc3Man9GlcNAc2 (G3M9) is indicated by the vertical arrow. The
positions of unglucosylated intermediates are indicated by numbers over the
respective peaks that refer to the mannose content of each intermediate.
CHO-K1 cells were labeled in 0.5 mM glucose (A). HADF cells were labeled in
either 0.5 mM glucose (B) or 5 mM glucose (C). (D) The percentage of mature
Glc3Man9GlcNAc2 LLO compared with Man2–5GlcNAc2 LLO intermediates in
HADF is indicated as a function of extracellular glucose. The calculation was
performed after determining the radioactivity of each oligosaccharide by
HPLC and then normalizing by mannose content. The apparent plateau below
0.2 mM glucose was because of the mass of the [3H]mannose label (2.3 mM)
itself. The arrow indicates 0.5 mM glucose, used throughout the remaining
experiments.












































While heat shock is not considered a classical inducer of the
UPR, it has been reported to stimulate synthesis of GRPs in
mammalian cells under certain conditions (30, 31). As shown in
Fig. 2 B and C, compared with TN and CSN, 42°C shock of
HADF caused a reproducible induction of GRP78 mRNA. By
comparison, 42°C shock, but neither TN nor CSN, induced
HSP70 mRNA. Thus, the cytoplasmic stress response was not
involved in stimulation by CSN. Seven different normal HADF
cultures (listed in Materials and Methods) responded to a 2-hr
42°C shock followed by a 6-hr recovery period at 37°C, increasing
the relative abundance of Glc3Man9GlcNAc2 by an average
factor of 3.4 6 0.3 (SEM). No direct dependence on cell passage
number was identified, although the effect of the UPR on LLO
synthesis became attenuated as these primary cells became
senescent (data not shown).
The increase of Glc3Man9GlcNAc2 was not because of de-
creased transfer from the LLO pool to nascent polypeptides, as
might be expected if acceptors in the ER became aggregated or
complexed with chaperones after stress, or if the oligosaccharyl-
transferase itself lost activity. First, when labeling reactions were
supplemented with unlabeled 0.1 mM mannose (Fig. 2 A, Right)
or 5 mM glucose (data not shown), Glc3Man9GlcNAc2 was the
predominant LLO in unstressed controls, and UPR effects were
greatly attenuated. Second, time courses (Fig. 3) with heat shock
and CSN showed that net transfer to protein was not affected
when LLO synthesis was stimulated. Interestingly, the time
course for heat shock was biphasic and not coincident with the
time course for GRP78 mRNA stimulation (compare with
GRP78 mRNA in Fig. 2C), suggesting differences in the respec-
tive regulatory mechanisms. Third, CHO-K1 cells and A375
melanoma cells labeled with 0.5 mM glucose produced mostly
Glc3Man9GlcNAc2 LLO and exhibited little or no increase of
Glc3Man9GlcNAc2 after treatment with CSN, DTT, or 42°C
shock. The A375 results also ruled out a contribution by previ-
ously reported stress effects on LLO synthesis (ref. 32; data not
shown). Taken together, these results demonstrate that the UPR
has little effect if LLO synthesis is already optimal, and that the
increase of Glc3Man9GlcNAc2 is not the result of accumulation
of untransferred LLO.
Similarly, the increase of Glc3Man9GlcNAc2 was not the result
of increased specific radioactivity of the intracellular mannose
label. If it was, radioactivity incorporated into protein and LLO
intermediates should have increased proportionally. However,
radioactivity in LLO intermediates was either unchanged or
diminished (Fig. 2 A), depending on the specific stress, and
radioactivity in the protein fraction was not affected (Fig. 3).
Fig. 2. The UPR stimulates synthesis of mature (Glc3Man9GlcNAc2) LLO in
HADF cells labeled in the presence of 0.5 mM glucose. (A) LLOs were analyzed
from HADF cells labeled with 2.3 mM [3H]mannose and 0.5 mM glucose in the
absence (Left) or presence (Right) of unlabeled 0.1 mM D-mannose. The graphs
show oligosaccharides from cells subjected to various stresses (dashed lines) as
well as from an equal number of cells from paired unstressed controls (solid
lines). Panel labels: ‘‘42°C (0)’’ and ‘‘42°C (6),’’ heat shock with either 0 or 6 hr
of recovery at 37°C; ‘‘CSN,’’ 200 mgyml for 24 hr; ‘‘AZC,’’ 5 mM for 2 hr (AZC,
azetidine-2-carboxylic acid); ‘‘DTT,’’ 200 mM for 20 min; and ‘‘Geld,’’ 2 mM for
24 hr (Geld, geldanamycin). The fold increase of Glc3Man9GlcNAc2 is indicated
by the number next to the peak. Because of a delay in detector activation, time
values for the dashed tracing in the heat shockyno recoveryy0.1 mM mannose
experiment were compensated by 4 min. (B) Northern blot [performed ac-
cording to standard procedures (24)] showing GRP78 (BiP) (GenBank
AA205990) and HSP70 (GenBank T74240) mRNA in control HADF, and after TN
treatment (5 mgyml, 6 hr), 2 hr 42°C heat shock (1 hr recovery), or CSN
treatment (200 mgyml, 24 hr). RNA signals were measured with a Fuji phos-
phorimager and normalized to actin. The fold increases calculated for GRP78
and HSP70 mRNAs relative to unstressed controls are presented below the
bands. Longer exposures demonstrated that all of the increased HSP70 signal
in the CSN and TN lanes resulted from spillover of signal from the adjacent
heat shock lane. (C) Time course of GRP78 and HSP70 induction after 2 hr, 42°C
heat shock. Results are expressed as for B.





































Further, the total radioactivity in the chloroformymethanoly
water (10:10:3) LLO fraction did not increase.
Glycopeptides obtained by proteolysis of the newly synthe-
sized glycoproteins are sensitive to subsequent endo H treatment
if the attached LLO-type oligosaccharides contain six or more
mannose residues. Cleavage is detectable by retarded elution of
3H-labeled compounds on gel filtration. Glycopeptides from a
CHO-K1 Lec35 mutant unable to extend LLO beyond the
five-mannose stage were completely resistant to endo H (29),
while glycopeptides from HADF maintained in 5 mM glucose
during growth and labeling were fully sensitive to endo H (Fig.
4A, Line 2). In contrast, after a 20-min incubation in 0.5 mM
glucose, much of the HADF glycopeptide fraction was resistant
to endo H, indicating transfer of Man2–5GlcNAc2 intermediates
(Fig. 4A, Line 1). Protein-bound Glc3Man9GlcNAc2 can be
processed into Glc1Man9GlcNAc2 recognition markers for cal-
reticulin and calnexin (9–12), but Man2–5GlcNAc2 are poorly
glucosylated (17) and only the glucosylated form of
Man5GlcNAc2 is a good ligand for calnexin and calreticulin in
vitro (33, 34). Therefore, an extended incubation in 0.5 mM
glucose should result in accumulation of unfolded protein,
induction of the UPR, and an increase in Glc3Man9GlcNAc2
LLO. As shown in Fig. 4, 0.5 mM glucose incubation for 12 hr
caused an increase of both GRP78 mRNA (Fig. 4B) and
Glc3Man9GlcNAc2 LLO (Fig. 4C). Thus, incubation in 0.5 mM
glucose for only 20 min is not sufficient to accumulate enough
unfolded nascent polypeptide for the UPR, but the UPR is
induced after 12 hr, in which case the dolichol pathway under-
goes a form of self-correction. Twelve hours of glucose depri-
vation also enhanced glucose uptake; transport of
2-deoxy[3H]glucose was 234.5 6 1.0% (SD) of control. Directly
increasing the glucose supply by this amount enhanced
Glc3Man9GlcNAc2 synthesis by 3-fold (Fig. 1D), while
Glc3Man9GlcNAc2 LLO was increased 11-fold by glucose de-
privation. Thus, the effect of glucose deprivation on LLO
synthesis is the result of the combination of UPR activation and
enhanced glucose transport.
The Man2–5GlcNAc2 content on nascent proteins was reduced
by UPR induction with CSN and nearly eliminated by extended
glucose deprivation (Fig. 4A, Lines 4 and 3, respectively).
This was consistent with the greater fold-increase of
Glc3Man9GlcNAc2 LLO and the greater decrease of LLO
intermediates after glucose deprivation (compare Figs. 2 and 4).
Fig. 3. Time course of stimulation of LLO synthesis in HADF. (Left) HADF cells
were incubated at 42°C for 2 hr and allowed to recover at 37°C for 0–24 hr, all
in 5 mM glucose. (Right) HADF were incubated with 200 mgyml CSN for the
indicated periods in 5 mM glucose. In both cases, cells were then labeled for
20 min with [3H]mannose in 0.5 mM glucose, and LLO were analyzed by HPLC.
Data were normalized to paired unstressed controls on the y-axis. E, Radio-
activity for Glc3Man9GlcNAc2 LLO. ■, The mannose radioactivity remaining
after exhaustive organic extraction and solubilization with 1% SDS—i.e.,
protein-associated oligosaccharides. As shown in Fig. 4, the majority of this
material must represent N-linked oligosaccharides because essentially all of
the resulting glycopeptides can be digested by endo H when the synthesis of
mature LLO is maximal.
Fig. 4. Extended glucose deprivation induces the UPR and reverses truncation
of lipid-linked and protein-bound oligosaccharides. (A) Prior to glycopeptide
analysis, HADF were either grown continuously in medium with 5 mM glucose
(Lines 1 and 2), with 0.5 mM glucose during the final 12 hr (Line 3), or with 5 mM
glucose plus 200 mgyml CSN during the final 24 hr (Line 4). To begin glycopeptide
analysis, cells were incubated in 0.5 mM (Lines 1, 3, and 4) or 5 mM (Line 2) glucose
for 20 min without radiolabel, followed by labeling with [3H]mannose for 20 min
in the same glucose concentration. Thus, the first 20-min period ensured com-
plete equilibration with the glucose concentration prior to radiolabeling. Tryptic
glycopeptides were isolated and incubated in the absence (data not shown) or
presence of endo H and fractionated on Bio-Gel P-4. Undigested glycopeptides
eluted as broad peaks between 90 and 160 min (data not shown), while oligo-
saccharidesreleasedbyendoHelutedlater.Tofacilitatedirectcomparisonsofthe
amount of endo H-resistant material, the tracings were normalized to peak
heights of the released oligosaccharides. Because CSN inhibits glucose removal,
the released oligosaccharides from the CSN sample eluted earlier than for other
samples. (B) mRNA for GRP78 was determined as in Fig. 2B. (C) LLO from cells
grown in 5 mM (solid line) or 0.5 mM (dashed line) glucose during the 12 hr prior
to labeling, then labeled for 20 min with [3H]mannose and 0.5 mM glucose, were
analyzed as in Fig. 2A.












































Similar results were obtained with Pronase glycopeptides, or
with tryptic peptides from cells grown continuously with swain-
sonine to block Golgi-type processing (a potential cause of endo
H resistance). Thus, prior activation of the UPR by CSN can
reduce accumulation of oligosaccharide intermediates, and sub-
sequent UPR activation by glucose deprivation can reverse it. In
both cases, the compositions of dolichol-linked and protein-
bound oligosaccharides are changed.
Discussion
These results establish an unexpected link between the UPR and
the dolichol pathway (Fig. 5). It is well known that the UPR
activates transcription of chaperones, such as the GRPs, and
folding enzymes, such as protein disulfide isomerase (1). The
data presented here suggest that UPR regulation can also affect
oligosaccharide ‘‘cofactors’’ in the cases of calnexin and calre-
ticulin, and raise the possibility that other folding cofactors (such
as ATP and oxidized glutathione) might also be regulated. It is
not known whether the effects described here are mediated by
a member of the Ire1p family (1) or a separate molecule, such
as PKR-like ER kinase (35). It is also not known whether these
effects involve transcriptional, translational, or posttranslational
regulation. Because inhibitors of RNA synthesis and protein
synthesis themselves have complex effects on the LLO pathway
(36), this could not be tested directly.
Similarly, the target of the UPR remains to be established. In
preliminary experiments, no differences between control and
UPR-induced HADF were observed for UDP-GlcNAc:doli-
chol-P GlcNAc-1-P transferase activity in vitro, mannose-P-
dolichol synthase activity in vitro, incorporation of [3H]mannose
into mannose phosphates or GDP-mannose in vivo, synthesis of
Man1–9GlcNAc2-P-P-dolichol from GDP-[3H]mannose in vitro,
or microsomal dolichol-P assessed by reactivity with mannose-
P-dolichol synthase (data not shown). Thus, a plausible expla-
nation is an increase in the intracellular concentration of man-
nose or a mannose precursor, because small amounts of extra-
cellular mannose (0.1 mM; Fig. 2 A) fully compensated for much
larger amounts of extracellular glucose (5 mM), in agreement
with earlier experiments on HADF (37). It is unlikely that this
could be due primarily to enhanced uptake of mannose or
glucose; after induction of the UPR by either CSN or 42°C
treatment, incorporation of extracellular [3H]mannose into total
water-soluble plus insoluble metabolites was never increased by
more than 30%, and, in some experiments, was unchanged (data
not shown). In contrast, control experiments testing various
extracellular mannose concentrations showed that increases of
approximately 10-fold would be necessary to account for the
UPR-dependent LLO changes. Heat shock increased uptake of
2-deoxy[3H]glucose by only 30%, and no increases were ob-
served with CSN or TN (data not shown). Unfortunately, all
attempts to determine the actual intracellular mannose were
unsuccessful.
Conceivably, the UPR could mobilize an intracellular store
of mannose, perhaps by degradation of cellular mannosyl
conjugates or by converting other nucleotide sugars into
GDP-mannose. Alternatively, an enzyme involved in the nor-
mal pathway leading to GDP-mannose, the immediate donor
for the first five mannose residues of the LLO as well as for
mannose-P-dolichol (itself the donor for the last four mannose
residues), might be regulated. Obvious candidates include
phosphomannomutase and phosphomannose isomerase, as
these could increase the f lux of mannose and glucose into
oligosaccharides. Another possibility is phosphofructokinase,
a highly regulated enzyme responsible for the committed step
in glycolysis. Inhibition would increase the steady-state con-
centrations of fructose 6-phosphate and all downstream man-
nosyl phosphates.
To accumulate LLO intermediates in HADF so that UPR-
dependent stimulation could be studied, it was necessary to
lower glucose in the culture medium approximately 10-fold
below the physiological range of concentrations in the blood.
What is the relevance of such a condition? It is difficult to know
what concentration of glucose would be truly appropriate for
dermal fibroblasts or other nonendothelial tissue cells because
little is understood about the glucose concentrations in the
interstitial f luids surrounding such cells. The results presented
here suggest that the LLO composition might be an indirect
indicator, but information on compositions of LLO extracted
directly from solid tissues is highly limited. One exception is the
pancreas; careful compositional analyses of LLO revealed that
Glc3Man9GlcNAc2 was no more abundant than truncated inter-
mediates (38, 39). Further, studies with glucose-sensing micro-
probes implanted into canine skin suggest that the glucose
concentrations at sites of inflammation are approximately 4-fold
lower than the circulatory concentration (40). Thus, the studies
reported here may be relevant for both healthy and damaged
tissue.
LLO profiles in CHO-K1 and other rapidly growing immortal
lines were not affected by 0.5 mM glucose, and there were no
appreciable UPR effects. More drastic reduction of glucose in
the medium (0.1 mM) did result in accumulation of truncated
LLO in CHO-K1 cells, but their relative amounts were unaf-
fected by 42°C or CSN treatment (J. Shang and M.A.L., unpub-
lished data). This suggests that the step regulated by the UPR
may be activated in immortal lines under basal conditions.
The calreticulin gene is responsive to the UPR (41), al-
though calnexin is not enhanced by TN, a strong UPR inducer
(42, 43). Because each is also a calcium-binding protein and
calreticulin has multiple proposed functions (44), alterations
of their concentrations in a UPR might have a multiplicity of
effects. Thus, for these lectin chaperones, a more desirable first
line of defense might be to regulate synthesis of their oligo-
saccharide ligands.
Carbohydrate-deficient glycoprotein syndrome (CDGS) is
often caused by defective LLO synthesis (45). These data may
therefore be relevant to the diagnosis of CDGS, which often
involves metabolic labeling of LLO in CDGS dermal fibro-
blasts with low-glucose medium and can yield highly variable
LLO profiles that are sometimes misleadingly similar to nor-
Fig. 5. The relationship between the ER UPR and dolichol-linked oligosac-
charide synthesis. When extracellular hexose levels fall or when one or more
metabolic steps are inhibited, truncated LLO intermediates accumulate and
are transferred to protein. Because such truncated intermediates do not yield
effective ligands for lectin chaperones, they cause inefficient protein folding
in the ER and trigger the UPR. In addition to activating the transcription of ER
chaperones such as the GRPs, the UPR also compensates directly for the hexose
deficiency, possibly by raising the intracellular mannose concentration. This
reduces the accumulation of LLO intermediates, increases the amount of
mature LLO transferred to protein, and facilitates protein folding.





































mal profiles (46–49). In our hands, variable results were
obtained with normal HADF if care was not taken to avoid
spurious stresses, such as nutrient deprivation, and to refeed
cells within 24 hr of labeling. Also, incubations with [3H]m-
annose concentrations above 2.3 mM increased the relative
amounts of mature LLO. Surprisingly, extended glucose (0.5
mM) deprivation of cultured CDGS type I-A cells for 12 hr
reversed defective LLO synthesis (50). The data presented
here suggest that this result may have been because of the
combined effects of UPR stimulation and enhanced glucose
transport, and raise the possibility that the UPR may be
chronically altered in CDGS cells.
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